Embecta Corp
NASDAQ:EMBC
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
9.28
20.1
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Operating Margin
Embecta Corp
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Embecta Corp
NASDAQ:EMBC
|
740.6m USD |
30%
|
|
| JP |
|
Hoya Corp
TSE:7741
|
8.4T JPY |
30%
|
|
| CH |
|
Alcon AG
SIX:ALC
|
31.9B CHF |
14%
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
129.9B DKK |
28%
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
12.3B USD |
16%
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.8B GBP |
15%
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
46.9B CNY |
38%
|
|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
6.2B USD |
2%
|
|
| CH |
|
Ypsomed Holding AG
SIX:YPSN
|
4.6B CHF |
28%
|
|
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
790.1B JPY |
18%
|
|
| US |
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
4.8B USD |
11%
|
Embecta Corp
Glance View
Embecta Corp. emerges as a notable player in the medical technology landscape, carved out as an independent entity after parting ways from Becton, Dickinson and Company. The separation was driven by a vision to concentrate efforts more precisely on the specialized field of diabetes management. Embecta inherits a rich heritage of innovation and expertise, focusing on the development and distribution of advanced medical devices designed to assist individuals in managing diabetes. Their primary offering revolves around insulin delivery systems, which are critical for the day-to-day management of diabetes by patients worldwide. Embecta’s capabilities are further augmented by their robust research and development wing, which relentlessly pursues advancements in technology to improve patient outcomes and enhance user experience. The company’s business model hinges on a combination of product sales and the establishment of lasting relationships with healthcare providers and patients. By ensuring a steady pipeline of disposable products and innovative technologies, Embecta not only generates recurring revenue through its insulin delivery solutions but also positions itself as a leader in the field of diabetic care. Their strategy encompasses a strong distribution network that reaches global markets, leveraging partnerships, acquisitions, and direct sales strategies to expand their footprint. With an eye on the future, Embecta is keenly aware of the growing prevalence of diabetes globally and continues to innovate and adapt, ensuring that their products meet the evolving needs of their end-users.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Embecta Corp's most recent financial statements, the company has Operating Margin of 30.5%.